Belvedere Trading’s Palvella Therapeutics PVLA Stock Holding History

Belvedere Trading’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-294	Closed	-$83K	–	618
2021 Q2	$83K	Buy	+294	New	+$64.5K	0.01%	281

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Belvedere Trading's PVLA Position: Q3 2021 in Review

Belvedere Trading sold out of Palvella Therapeutics (PVLA) in Q3 2021, closing a stake of 294 shares — an estimated $83K sold.

Belvedere Trading first reported a position in PVLA in Q2 2021 and held it in 1 quarter. The position peaked at $83K in Q2 2021. 75 funds tracked by Wall St. Rank hold PVLA as of Q3 2021.

Belvedere Trading reported no remaining Palvella Therapeutics position as of Q3 2021 after selling out during the quarter.
Belvedere Trading sold 294 Palvella Therapeutics shares in Q3 2021, an estimated $83K.
Belvedere Trading first reported a position in Palvella Therapeutics in Q2 2021 and held it in 1 quarter.
Belvedere Trading's Palvella Therapeutics position peaked at $83K in Q2 2021.
75 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2021.

Based on Belvedere Trading's 13F filing for Q3 2021, filed 19 Oct 2021.